Marguerite T. Parisi

Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial

Rajen Mody, Arlene Naranjo, Collin Van Ryn et al. · The Lancet Oncology · 2017 · 273 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Pediatric Radiopharmaceutical Administered Doses: 2010 North American Consensus Guidelines

Michael J. Gelfand, Marguerite T. Parisi, S. Ted Treves · Journal of Nuclear Medicine · 2011 · 228 citations · Full text

Medicine, Pediatrics, Radiology +17

Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

Alice L. Yu, Andrew L. Gilman, M. Fevzi Özkaynak et al. · Clinical Cancer Research · 2021 · 216 citations · Full text

Life Sciences, Immunology, Oncology +17

Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children’s Oncology Group

Gregory A. Yanik, Marguerite T. Parisi, Barry L. Shulkin et al. · Journal of Nuclear Medicine · 2013 · 210 citations · Full text

Medicine, Nuclear Medicine, Oncology +16

Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children’s Oncology Group

Rajen Mody, Alice L. Yu, Arlene Naranjo et al. · Journal of Clinical Oncology · 2020 · 191 citations · Full text

Medicine, Oncology, Pharmacotherapy +12